Novo Nordisk | NVO - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
ANI Pharmaceuticals USD 31.48M 18.04M 2025-12
Aurora Cannabis CAD -1.58M 48.55M 2025-12
Bausch Health Companies USD 56M 162M 2025-12
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Canopy Growth CAD -62.26M 60.84M 2025-12
Corcept Therapeutics USD 9.91M 5.33M 2025-12
Drreddys Laboratories INR 15.43B 1.96B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Merck USD 3.42B 3.32B 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Novartis USD 3.84B 802M 2026-03
Novo Nordisk DKK 33.8B 3.23B 2025-06
Novo Nordisk DKK 25.52B 8.29B 2025-09
Pacira USD 571K 8.95M 2025-12
Perrigo USD -1.33B 1.35B 2025-12
Phibro Animal Health USD 38.62M 1.26M 2025-12
Prestige Brands USD 61.81M 7.32M 2025-12
Sanofi EUR -1.16B 5.5B 2025-12
Supernus Pharmaceuticals USD -5.95M 4.04M 2026-03
Zoetis USD 761M 126M 2025-12